Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status

Gene Therapy

Volumn 7, Issue 22, 2000, Pages 1925-1929

  Heise, C ^a   Ganly, I ^b   Kim, Y T ^b   Sampson Johannes, A ^a   Brown, R ^b   Kirn, D ^a  

^a ONYX PHARMACEUTICALS   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adenovirus; Intraperitoneal; Ovarian cancer; P53

Indexed keywords

CISPLATIN; PROTEIN P53;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOENGINEERING; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; GENE DELETION; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ULTRAVIOLET RADIATION; VIRUS GENE; VIRUS INACTIVATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MUS MUSCULUS; ONYX;

EID: 0033665576     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301319     Document Type: Article

References (32)

1. Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
3. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
4. Ovarian cancer, from the laboratory to the clinic: Challenges for the future
5. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas
6. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
7. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
8. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
9. Abnormal structure and function of the p53 gene in human ovarian carcinoma cell lines
10. Implications of the p53 tumor-suppressor gene in clinical oncology
11. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells
12. Characterization of a cis-diammine dichloro-platinum resistant human ovarian cell line and its use in evaluation of platinum analogues
13. Increased accumulation of p53 in cisplatin-resistant ovarian cells
14. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
15. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
16. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
17. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
18. p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication
19. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
20. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
21. p53 Mutation and MDM2 amplification in human soft tissue sarcomas
22. A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
23. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer
24. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer
25. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
26. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
27. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects
28. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma
29. Evaluation of adenovirus p53-mediated 'bystander effect' in vivo
30. The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells
31. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
32. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer